Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCENT II: Infliximab in Fistulizing Crohn's Disease
NCT00207766Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2000
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Infliximab Maintenance with Placebo Maintenance (2 arms). Primary endpoint: Reduction in the number of draining fistulas. Started Jun 2000; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00207766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00207766.